tradingkey.logo
tradingkey.logo
Search

Amylyx Pharmaceuticals Inc

AMLX
Add to Watchlist
20.310USD
-0.440-2.12%
Close 07-31 16:00ETQuotes delayed by 15 min
2.26BMarket Cap
LossP/E TTM

AMLX Financials

See Amylyx Pharmaceuticals Inc's financials through an all-in-one data dashboard designed for smart investors. This provides you with financial analysis by organizing complex financial statements into customizable views. Access the latest annual financial report or break down performance quarter-by-quarter using the income statement, balance sheet, and cash flow statement. With real-time financial indicators at your fingertips, monitoring a company's market health over time has never been easier.

Amylyx Pharmaceuticals Inc Earnings Date

Latest Release
May 7, 2026
EPS / Forecast
-0.37/-0.33
Revenue / Forecast
0.00/0.00
Period
FY2025 Earnings
Revenue(YoY)
--
-100.00%
EPS(YoY)
-1.53
65.44%
Analyst Rating
BUY
2026/08/02
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
FY2021Q1
Financial Indicators
EPS
10.88%-0.37
45.20%-0.30
65.50%-0.37
56.50%-0.46
76.07%-0.42
-881.69%-0.55
-444.52%-1.07
-425.51%-1.07
-7524.55%-1.75
110.74%0.07
--0.31
--0.33
--0.02
---0.65
---2.77
----
----
----
----
----
----
Revenue
--0.00
100.00%0.00
-100.00%0.00
100.00%0.00
-100.00%0.00
-100.61%-665.00K
-99.59%416.00K
-101.04%-1.02M
24.10%88.64M
395.54%108.45M
29666.09%102.69M
--98.22M
--71.43M
--21.89M
--345.00K
----
----
-100.00%0.00
----
----
----
Net Profit
-14.97%-41.28M
12.11%-33.00M
52.70%-34.39M
42.99%-41.44M
69.77%-35.91M
-893.62%-37.55M
-447.98%-72.70M
-429.35%-72.70M
-7652.00%-118.79M
111.08%4.73M
138.87%20.89M
140.83%22.07M
103.29%1.57M
-50.66%-42.70M
---53.76M
-146.63%-54.07M
-229.46%-47.85M
-229.89%-28.34M
----
---21.92M
---14.52M
Net Margin
----
----
----
----
----
----
-86002.33%-17476.92%
----
-6185.35%-134.01%
102.24%4.36%
--20.35%
--22.47%
--2.20%
---195.13%
---45122.03%
----
----
----
----
----
----
Gross Margin
----
----
----
----
----
----
-199.53%-94.47%
----
-21.14%73.03%
4.89%91.37%
--94.92%
--94.32%
--92.60%
--87.11%
--50.14%
----
----
----
----
----
----
Debt to assets ratio
----
----
----
----
----
----
----
----
----
--0.00%
--0.00%
--0.00%
--0.00%
--0.00%
--0.00%
----
----
----
----
----
----
Revenue
--0.00
100.00%0.00
-100.00%0.00
100.00%0.00
-100.00%0.00
-100.61%-665.00K
-99.59%416.00K
-101.04%-1.02M
24.10%88.64M
395.54%108.45M
29666.09%102.69M
--98.22M
--71.43M
--21.89M
--345.00K
----
----
-100.00%0.00
----
----
----
Operating profit
-15.81%-43.78M
9.96%-36.60M
8.70%-36.03M
19.80%-42.86M
-27.58%-37.80M
-2202.07%-40.65M
-310.78%-39.46M
-364.52%-53.44M
-1343.25%-29.63M
104.34%1.93M
134.23%18.72M
137.23%20.20M
95.71%-2.05M
-57.49%-44.59M
---54.68M
-191.89%-54.25M
-271.57%-47.81M
-229.55%-28.32M
----
---18.59M
---12.87M
Net Profit
-14.97%-41.28M
12.11%-33.00M
52.70%-34.39M
42.99%-41.44M
69.77%-35.91M
-893.62%-37.55M
-447.98%-72.70M
-429.35%-72.70M
-7652.00%-118.79M
111.08%4.73M
138.87%20.89M
140.83%22.07M
103.29%1.57M
-50.66%-42.70M
---53.76M
-146.63%-54.07M
-229.46%-47.85M
-229.89%-28.34M
----
---21.92M
---14.52M
Current assets
31.87%285.02M
70.86%323.67M
44.08%353.38M
-42.80%186.89M
-47.35%216.14M
-59.23%189.43M
-43.50%245.26M
-23.55%326.72M
5.52%410.53M
21.60%464.67M
152.10%434.11M
97.74%427.39M
46.54%389.05M
264.11%382.13M
32.52%172.20M
--216.14M
--265.49M
--104.95M
--129.94M
----
----
Total current liabilities
-10.96%15.97M
-20.13%22.69M
-52.16%25.79M
-69.43%21.42M
-80.43%17.93M
-65.38%28.41M
18.19%53.91M
9.36%70.08M
77.54%91.64M
76.02%82.04M
39.73%45.62M
135.91%64.08M
86.30%51.62M
167.93%46.61M
115.55%32.65M
--27.16M
--27.71M
--17.40M
--15.15M
----
----
Total assets
33.65%293.60M
71.79%332.64M
44.68%362.74M
-41.41%194.60M
-47.38%219.68M
-62.58%193.63M
-46.27%250.71M
-26.77%332.16M
2.33%417.46M
32.19%517.45M
157.15%466.58M
101.38%453.59M
48.65%407.96M
270.64%391.45M
39.08%181.44M
--225.24M
--274.44M
--105.61M
--130.46M
----
----
Total liabilities
11.96%20.44M
-5.14%27.39M
-43.60%30.75M
-62.29%26.72M
-80.37%18.26M
-65.64%28.87M
13.13%54.51M
5.40%70.85M
68.18%93.02M
65.25%84.02M
28.78%48.18M
107.15%67.22M
65.14%55.31M
191.70%50.85M
146.49%37.41M
--32.45M
--33.49M
--17.43M
--15.18M
----
----
Total equity
35.62%273.16M
85.27%305.26M
69.21%332.00M
-35.76%167.88M
-37.92%201.42M
-61.99%164.76M
-53.11%196.20M
-32.37%261.31M
-8.00%324.44M
27.25%433.43M
190.50%418.40M
100.41%386.37M
46.36%352.65M
286.25%340.61M
24.94%144.03M
--192.79M
--240.95M
--88.18M
--115.28M
----
----
Net operating income
7.39%-36.88M
52.71%-27.90M
26.95%-30.37M
62.08%-25.25M
-8043.97%-39.82M
-535.45%-59.01M
-704.22%-41.57M
-873.38%-66.58M
90.36%-489.00K
127.27%13.55M
88.00%-5.17M
118.53%8.61M
87.52%-5.07M
-75.96%-49.70M
---43.08M
-256.11%-46.46M
-221.40%-40.63M
-217.78%-28.24M
----
---13.05M
---12.64M
Net investment
183.06%36.26M
-54.65%29.47M
-86.51%5.24M
179.40%22.99M
-5430.77%-43.66M
210.54%64.98M
135.91%38.82M
-123.50%-28.96M
-98.54%819.00K
109.17%20.93M
-228.61%-108.09M
2661.59%123.22M
156.38%55.99M
-8208.74%-228.18M
--84.04M
--4.46M
-709264.29%-99.31M
1963.58%2.81M
----
--0.00
---14.00K
Net financing
-95.10%3.22M
-289.09%-208.00K
239407.50%191.61M
-214.81%-31.00K
50023.66%65.66M
-52.17%110.00K
-91.00%80.00K
-98.05%27.00K
-87.40%131.00K
-99.90%230.00K
--889.00K
267.15%1.38M
-99.48%1.04M
21899.25%232.16M
--0.00
-141.55%-828.00K
673.15%200.46M
-190.41%-1.06M
----
--1.99M
--25.93M

FAQs

What are the current assets of Amylyx Pharmaceuticals Inc?

According to Amylyx Pharmaceuticals Inc's FY2025 earnings report, its current assets were 323.67M, with a year-on-year change of 70.86.

What are the total assets of Amylyx Pharmaceuticals Inc?

According to Amylyx Pharmaceuticals Inc's FY2025 earnings report, its total assets of Amylyx Pharmaceuticals Inc were 332.64M, with a year-on-year change of 71.79.

What are the total liabilities of Amylyx Pharmaceuticals Inc?

According to Amylyx Pharmaceuticals Inc's FY2025 earnings report, its total liabilities of Amylyx Pharmaceuticals Inc were 27.39M, with a year-on-year change of -5.14.

What is the total equity of Amylyx Pharmaceuticals Inc?

According to Amylyx Pharmaceuticals Inc's FY2025 earnings report, its total equity of Amylyx Pharmaceuticals Inc was 305.26M, with a year-on-year change of 85.27.

What is the net operating income of Amylyx Pharmaceuticals Inc?

According to Amylyx Pharmaceuticals Inc's FY2025 earnings report, its net operating income of Amylyx Pharmaceuticals Inc was -153.29M, with a year-on-year change of 6.06.

What is the net investment of Amylyx Pharmaceuticals Inc?

According to Amylyx Pharmaceuticals Inc's FY2025 earnings report, its net investment of Amylyx Pharmaceuticals Inc was 14.04M, with a year-on-year change of -81.44.

What is the net financing of Amylyx Pharmaceuticals Inc?

According to Amylyx Pharmaceuticals Inc's FY2025 earnings report, its net financing of Amylyx Pharmaceuticals Inc was 257.03M, with a year-on-year change of 73758.91.

What is the Earnings Per Share (EPS) of Amylyx Pharmaceuticals Inc?

According to Amylyx Pharmaceuticals Inc's FY2025 earnings report, its Earnings Per Share (EPS) was -1.53, with a year-on-year change of 65.44.

What is the net income of Amylyx Pharmaceuticals Inc?

According to Amylyx Pharmaceuticals Inc's FY2025 earnings report, its net income was -144.74M, with a year-on-year change of 52.03.

What is the Return on Equity (ROE) of Amylyx Pharmaceuticals Inc?

According to Amylyx Pharmaceuticals Inc's FY2025 earnings report, its Return on Equity (ROE) was -61.59, with a year-on-year change of 38.95.

What is the Return on Assets (ROA) of Amylyx Pharmaceuticals Inc?

According to Amylyx Pharmaceuticals Inc's FY2025 earnings report, its Return on Assets (ROA) was -55.00, with a year-on-year change of 35.19.

What is the operating profit of Amylyx Pharmaceuticals Inc?

According to Amylyx Pharmaceuticals Inc's FY2025 earnings report, its operating profit was -153.29M, with a year-on-year change of 6.06.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.